Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018 (2018), Article ID 3503858, 7 pages
https://doi.org/10.1155/2018/3503858
Research Article

Genetic Association of Interleukin-31 Gene Polymorphisms with Epithelial Ovarian Cancer in Chinese Population

1Laboratory of Molecular and Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610061, China
2Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China
3Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, China
4Department of Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610061, China
5Department of Forensic Medicine, Nanjing Medical University, Nanjing 210029, China

Correspondence should be addressed to Bin Zhou and Lin Zhang

Received 5 August 2017; Revised 30 October 2017; Accepted 16 November 2017; Published 1 February 2018

Academic Editor: Silvia Angeletti

Copyright © 2018 Chenlu Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Jammal, A. Martins-Filho, T. P. Silveira, E. F. Murta, and R. S. Nomelini, “Cytokines and prognostic factors in epithelial ovarian cancer,” Clinical Medicine Insights: Oncology, vol. 10, no. 10, pp. CMO.S38333–CMO.S38336, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Miki, J. Swensen, D. Shattuck-Eidens et al., “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1,” Science, vol. 266, no. 5182, pp. 66–71, 1994. View at Publisher · View at Google Scholar
  3. K. B. Kuchenbaecker, S. J. Ramus, J. Tyrer et al., “Identification of six new susceptibility loci for invasive epithelial ovarian cancer,” Nature Genetics, vol. 47, no. 2, pp. 164–171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Havrilesky, K. M. Darcy, H. Hamdan et al., “Prognostic significance of P53 mutation and P53 overexpression in advanced epithelial ovarian cancer: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3814–3825, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Ferretti, C. Tripodo, G. Pagnan et al., “The interleukin (Il)-31/Il-31r axis contributes to tumor growth in human follicular lymphoma,” Leukemia, vol. 29, no. 4, pp. 958–967, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Lange, J. Gleń, M. Zabłotna et al., “Interleukin-31 polymorphisms and serum Il-31 level in patients with mastocytosis: correlation with clinical presen-Tation and Pruritus,” Acta Dermato Venereologica, vol. 97, no. 1, pp. 47–53, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. S. R. Dillon, C. Sprecher, A. Hammond et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nature Immunology, vol. 5, no. 7, pp. 752–760, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. M. Hermanns, “Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology,” Cytokine & Growth Factor Reviews, vol. 26, no. 5, pp. 545–558, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Ishii, J. Wang, W. Zhang et al., “Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders,” Blood, vol. 113, no. 23, pp. 5942–5950, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. L. A. Nattkemper, M. E. Martinez-Escala, A. B. Gelman et al., “Cutaneous T-cell lymphoma and pruritus: the expression of Il-31 and its receptors in the skin,” Acta Dermato Venereol, vol. 96, no. 7, pp. 894–898, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ohmatsu, M. Sugaya, H. Suga et al., “Serum Il-31 levels are increased in patients with cutaneous T-cell lymphoma,” Acta Dermato Venereologica, vol. 92, no. 3, pp. 282–3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, and E. Chyczewska, “Novel cytokines: Il-27, Il-29, Il-31 and Il-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?” Experimental Oncology, vol. 34, no. 4, pp. 348–353, 2012. View at Google Scholar
  13. W. K. Ip, C. K. Wong, M. L. Y. Li, P. W. Li, P. F. Y. Cheung, and C. W. K. Lam, “Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response,” Immunology, vol. 122, no. 4, pp. 532–541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Zeng, Z. Zhang, Q.-Q. Gao et al., “Clinical significance of serum interleukin-31 and interleukin-33 levels in patients of endometrial cancer: a case control study,” Disease Markers, vol. 2016, Article ID 9262919, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Chattopadhyay, E. Tracy, P. Liang, O. Robledo, S. Rose-John, and H. Baumann, “Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells,” Journal of Biological Chemistry, vol. 282, no. 5, pp. 3014–3026, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Davidi, E. Fremder, T. Kan et al., “The antiangiogenic role of the pro-inflammatory cytokine interleukin-31,” Oncotarget, vol. 8, no. 10, pp. 16430–16444, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. C. C. Lan, H. P. Tu, C. S. Wu et al., “Distinct Spink5 and Il-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population,” Experimental Dermatology, vol. 20, no. 12, pp. 975–979, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rabenhorst and K. Hartmann, “Interleukin-31: a novel diagnostic marker of allergic diseases,” Current Allergy and Asthma Reports, vol. 14, no. 4, p. 423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. H. T. Huang, J. M. Chen, J. Guo, Y. Lan, and Y. S. Wei, “The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus,” Rheumatology International, vol. 36, no. 6, pp. 799–805, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Song, Y. Peng, B. Zhou et al., “Associations between Interleukin-31 gene polymorphisms and dilated cardiomyopathy in a Chinese population,” Disease Markers, vol. 2017, Article ID 4191365, 10 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Folkman, “Anti-angiogenesis: new concept for therapy of solid tumors,” Annals of Surgery, vol. 175, no. 3, pp. 409–416, 1972. View at Publisher · View at Google Scholar
  22. Y. Shaked, E. Henke, J. M. L. Roodhart et al., “Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents,” Cancer Cell, vol. 14, no. 3, pp. 263–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Shaked and R. S. Kerbel, “Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy,” Cancer Research, vol. 67, no. 15, pp. 7055–7058, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Balazs, Kaplan-Meier Plotter, 2009, http://kmplot.com.